KLK3 and hepatocellular carcinoma: For prostate tissue, the probasin promoter (to drive E1A) and the enhancer element of prostate-specific antigen (PSA) (to drive E1B) were used [21] and for hepatocellular carcinoma (HCC) the alpha-feto protein (AFP) promoter [22].